Since 2004 Medigard has been an R&D focused company; designing and developing a suite of safety medical devices and associated products. Research and development lies at the core of Medigard’s operations. Our goal is to continually extend our R&D program to produce safer, more effective, more efficient devices for the medical industry.

The Medigard team is continually developing existing products and creating other new products. Our research is rigorously protected by patents for all developments, inventions and improvements.

Click here for information on Medigard’s patents.

Blood Collection Device

In 2008/2009 Medigard advanced our packaging of the BCD without compromising the integrity of the vacuum.

Flash Back Needle

Medigard has designed a Flash Back Needle as a complementary product for the BCD. The Flash Back Needle is expected to be ready for production in 2011. The current timeline means it will be bundled with the BCD from 2012.

It is expected about 50 percent of BCDs will be bundled with our Flash Back Needle.

Flash back needles allow healthcare workers immediate visual confirmation of a successful venipuncture and are expected to become standard attachment for BCDs.

The Flash Back Needle market is potentially worth USD$100 million.

Retractable Syringe

Around 2,000 samples of the 3mL retractable syringe were made available for standards testing and simulated clinical trials in 2009 in preparation for an application to the FDA.

The design of a 1mL retractable syringe has been progressed. Other products are also being progressed which can be bundled with others in the Medigard product line.

Prefilled Syringe

Design is completed and prototyping underway on a Medigard prefilled syringe.

Prefilled syringes are a modern way to produce and administer some drugs. The advantages include convenience and ease of handling as well as greater safety and a reduction of drug overfill.

The existing prefilled syringe market in the US is worth around USD$200 million. The world market is estimated at USD$400 million.

The US market is expected to grow at a rate of 20 percent annually.